Buyer beware: Off-brand Ozempic, Zepbound and other weight loss products carry undisclosed risks for consumers

As the demand for weight loss injectables soars, so too does the market for off-brand alternatives, some of which may not be safe or effective.& Michael Siluk/UCG, Universal Images Group Editorial via Getty Images by C. Michael White, University of Connecticut In just a few years, brand-name injectable drugs such as Ozempic, Wegovy, Mounjaro and Zepbound have rocketed to fame as billion-dollar annual sellers for weight loss as well as to control blood sugar levels and reduce the risk of heart disease. But the price of these injections is steep: They cost about US$800-$1,000 per month, and if used for weight loss alone, they are not covered by most insurance policies. Both drugs mimic the naturally occurring hormone GLP-1 to help regulate blood sugar and reduce cravings. They can be taken only with a prescription. The Food and Drug Administration announced an official shortage of the active ingredients in these drugs in 2022, but on Oct. 2, 2024, the agency announced that the shortage has been resolved for the medicine tirzepatide, the active ingredient in Mounjaro and Zepbound. Despite the soaring demand and limited supply of these drugs, there are no generic versions available. This is because the patents for...